Therapeutic Advances and Novel Drug Treatment Opportunities in the Neuromuscular Disorders Area
This Editorial examines how the emergence of new therapies impacts the survival and motility of children and adults with spinal muscular atrophy and Duchenne or Becker muscular dystrophy, limb girdle muscular dystrophy, late-onset glycogenosis type 2, myotonic dystrophy and facioscapulohumeral dystrophy.